RENB (Renovaro Inc.) קצב צמיחת רווח למניה בשנה הנוכחית

The minimal environmental footprint of the IT infrastructure contrasts with significant volatility risks and the uncertainty of clinical trials. The final annual EPS growth rate shown on this GURU.Markets chart demonstrates a trend where 0.00 reflects the baseline level of the metric. This underscores the ambitions of Renovaro Inc. (RENB) to create personalized cancer therapies using artificial intelligence to strengthen its scientific authority.
פילוחים אנליטיים ודוחות נתונים של חברת renovarobio.com (RENB)

For Renovaro Inc. (RENB), profit dynamics remain independent of economic cycles due to the specific nature of immunotherapy development. The current YoY EPS change reflects the percentage shift in net income per share compared to the same period last year. This calculation allows for an assessment of the capitalization efficiency of research phases. It is critical for investors to track this trend to understand the growth rate of the business value. The stability of this metric confirms the biotech's resilience to macroeconomic shocks.